Add to a list

Inactive Instrument

NEOPROBE Stock OTC Bulletin Board

NEOP

US6405181065

Biotechnology & Medical Research

OTC Markets Traded

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

01-30	Motion for Asset Sale Approved for Navidea Biopharmaceuticals, Inc.	CI
01-27	Notice of Asset Purchase Agreement Filed by Navidea Biopharmaceuticals, Inc.	CI

on all subscriptions*

Exceptional extension!

Enjoy this offer

* See conditions under "Our services"

Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It is developing multiple precision-targeted products based on its Manocept platform to enhance patient care by identifying the sites and pathways of undetected disease. The Companyâ€™s business is focused on two primary types of drug products, such as diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of its Manocept platform, and therapeutic development programs, including therapeutic applications of its Manocept platform. It has developed processes for producing the first four therapeutic Manocept immuno-construct series, the Manocept doxorubicin (MAN-DOX) series, which is designed to specifically target and kill or modify activated CD206+ macrophages by delivering doxorubicin, a Manocept paclitaxel series (MAN-PAC), and a Manocept Bisphosphonate series (MAN-BIS).

Employees

Sector

Biotechnology & Medical Research

More about the company

-40%: Exceptional extension

SEIZE THE OFFER!

Market Cap	5.52M 4.85M 4.47M 4.18M 7.84M 523M 7.97M 53.65M 20.77M 257M 20.72M 20.27M 892M	P/E 2021	-2.5x	P/E 2022	-0.38x
Enterprise Value	5.96M 5.24M 4.82M 4.52M 8.46M 565M 8.6M 57.92M 22.42M 277M 22.37M 21.89M 963M	EV / Sales 2021	50.2x	EV / Sales 2022	110x
Free-Float	100%	Yield 2021 *	-	Yield 2022	-

01-30	Motion for Asset Sale Approved for Navidea Biopharmaceuticals, Inc.	CI
01-27	Notice of Asset Purchase Agreement Filed by Navidea Biopharmaceuticals, Inc.	CI
01-23	Notice of Successful Bidder Filed by Navidea Biopharmaceuticals, Inc.	CI
12-30	Reorganization Plan Filed by Navidea Biopharmaceuticals, Inc.	CI
12-11	Bidding Procedure Approved for Navidea Biopharmaceuticals, Inc.	CI
11-24	Motion for Asset Sale Filed by Navidea Biopharmaceuticals, Inc.	CI
11-07	Motion for Case Dismissal or Order Limiting the Debtor-in-Possession?s Powers, Equitably Subordinating Certain Claims or Expanding the Subchapter V Trustee?s Powers Withdrawn for Navidea Biopharmaceuticals, Inc.	CI
11-07	Final DIP Financing Approved for Navidea Biopharmaceuticals, Inc.	CI
11-03	Motion for Case Dismissal or Order Limiting the Debtor-in-Possession?s Powers, Equitably Subordinating Certain Claims or Expanding the Subchapter V Trustee?s Powers Filed for Navidea Biopharmaceuticals, Inc.	CI
09/10/25	Interim DIP Financing Approved for Navidea Biopharmaceuticals, Inc.	CI
09/10/25	Navidea Biopharmaceuticals files for bankruptcy	RE
02/10/25	Navidea Biopharmaceuticals, Inc. Filed for Bankruptcy	CI
04/07/24	Navidea Biopharmaceuticals, Inc. Announces Results of Exploratory Analysis Completed on July 2, 2024	CI

09/10/25	Navidea Biopharmaceuticals Inc. Files for Bankruptcy	AQ
04/12/23	Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release	AQ
15/11/23	Navidea: Q3 Earnings Snapshot	AQ
06/10/23	Navidea Biopharmaceuticals, Inc. Announces NYSE American’s Decision to Suspend Trading In Its Common Stock	BU
10/08/23	Navidea Biopharmaceuticals, Inc. NAVB Requests Oral Hearing With NYSE Hearing Panel	BU

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LONZA GROUP AG	+2.96%	+4.08%	-8.03%	-2.24%	43.24B
REVOLUTION MEDICINES, INC.	+2.23%	+8.26%	+323.35%	+564.22%	35.25B
BEONE MEDICINES AG	+1.59%	+4.63%	+7.23%	+54.02%	30.22B
IQVIA HOLDINGS INC.	+2.07%	-4.40%	+10.38%	-19.99%	28.01B
CELLTRION, INC.	-4.75%	-8.29%	+3.90%	+13.88%	24.08B
ASCENDIS PHARMA A/S	+4.64%	+3.20%	-	-	14.16B
MEDPACE HOLDINGS, INC.	+3.91%	+2.57%	+53.41%	+111.95%	13.01B
EUROFINS SCIENTIFIC SE	+2.77%	+2.93%	+9.65%	+11.90%	12.7B
IONIS PHARMACEUTICALS, INC.	+0.13%	+3.97%	+101.73%	+91.70%	12.54B
Average	+1.69%	-0.78%	+62.70%	+103.18%	23.69B
Weighted average by Cap.	+1.58%	-0.72%	+69.07%	+120.36%

	2021	2022
Net sales	532K 467K 430K 403K 755K 50.35M 767K 5.17M 2M 24.7M 2M 1.95M 85.86M	65.65K 57.68K 53.14K 49.75K 93.21K 6.22M 94.78K 638K 247K 3.05M 246K 241K 10.61M
Net income	-11.73M -10.31M -9.5M -8.89M -16.66M -1.11B -16.94M -114M -44.14M -545M -44.04M -43.09M -1.9B	-15.18M -13.33M -12.29M -11.5M -21.55M -1.44B -21.91M -148M -57.1M -705M -56.98M -55.75M -2.45B
Net Debt	-3.48M -3.06M -2.82M -2.64M -4.94M -330M -5.03M -33.84M -13.1M -162M -13.07M -12.79M -562M	440K 386K 356K 333K 624K 41.66M 635K 4.27M 1.65M 20.44M 1.65M 1.62M 71.04M

NEOPROBE Stock OTC Bulletin Board

Stocks

NEOP

US6405181065

Biotechnology & Medical Research

Valuation: NEOPROBE

Latest news : NEOPROBE

Press Releases: NEOPROBE

Managers and Directors: NEOPROBE

Other Biotechnology & Medical Research

Financials

Company Profile